POINT Biopharma Global Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PNT research report →
About the company
POINT Biopharma Global Inc. functions as a radiopharmaceutical company dedicated to the advancement and commercialization of specialized radioligand therapies designed to combat various cancerous conditions. Its two primary investigational treatments, both currently in Phase III clinical trials, are PNT2002, a radioligand engineered to target prostate-specific membrane antigen (PSMA) for addressing metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin-targeted radioligand being evaluated for the treatment of neuroendocrine tumors.
- CEO
- Joe A. McCann
- IPO
- 2020
- Employees
- 129
- HQ
- Indianapolis, IN, US
Price Chart
- Market Cap
- $1.33B
- P/E
- 12.02
- P/S
- 5.88
- P/B
- 2.43
- EV/EBITDA
- 8.21
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- 55.40%
- Net Margin
- 43.38%
- ROE
- 26.49%
- ROIC
- 19.10%
- Revenue
- $226.58M · 0.00%
- Net Income
- $98.29M · 314.13%
- EPS
- $1.04 · 267.74%
- Op Income
- $125.52M
- FCF YoY
- 419.16%
- 52W High
- $14.35
- 52W Low
- $6.57
- 50D MA
- $13.22
- 200D MA
- $9.77
- Beta
- -0.00
- Avg Volume
- 3.85M
Get TickerSpark's AI analysis on PNT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 44,749 |
| Dec 26, 23 | GOODMAN JONATHAN R. | other | 41,872 |
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 35,872 |
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 25,000 |
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 25,614 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 26,904 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 4,932 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 77,958 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 98,358 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 70,000 |
Our PNT coverage
Recent articles, reports, and earnings notes.
No research on PNT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PNT report →Similar companies
Peers in the same neighborhood.